文献速递复苏、休克与脓毒症创伤与烧伤

步行血库新鲜全血用于创伤性失血性休克:系统评价与荟萃分析

Fresh whole blood from walking blood banks for patients with traumatic hemorrhagic shock: A systematic review and meta-analysis.
PubMed 文献 · J Trauma Acute Care Surg · 2020-01-01
一句话结论步行血库新鲜全血用于创伤性失血性休克患者,总体生存与非新鲜全血相当,但证据质量低,需谨慎

该系统评价与荟萃分析纳入27项研究(2006—2020年发表),报告超过10000单位步行血库新鲜全血输注给超过3000例患者。新鲜全血组患者损伤更严重。8项比较研究显示新鲜全血与非新鲜全血组生存率等效(OR 1.00,95%CI 0.65-1.55,p=0.61)。但质量最高的研究(按生理和损伤特征匹配)报告新鲜全血组死亡的调整OR为0.27(95%CI 0.13-0.58,p<0.01)。证据总体质量低或极低,步行血库可作为应急韧性措施但需谨慎,应进行前瞻性评估。

要点

  • 8项比较研究显示,步行血库新鲜全血与非新鲜全血复苏生存率等效(OR 1.00,95%CI 0.65-1.55,p=0.61),尽管新鲜全血组损伤更严重。
  • 质量最高的匹配研究(按生理和损伤特征匹配)报告新鲜全血组死亡的调整OR为0.27(95%CI 0.13-0.58,p<0.01)。
  • 证据质量总体为低或极低,仅一项研究为中等质量;可能低估潜在不良事件。
  • 步行血库可作为孤立社区和危机(包括COVID-19大流行)期间的应急韧性措施,但作者建议仍需谨慎。
  • 作者建议步行血库应接受前瞻性评估,以优化救治并指导政策。

适用人群与场景

  • 创伤性失血性休克患者,接受步行血库新鲜全血输注。
  • 排除仅报告来自传统血库的全血的研究。

研究设计与关键结果

  • 系统评价与荟萃分析纳入27项研究(2006—2020年发表),报告超过10000单位新鲜全血输注给超过3000例患者(并非所有研究均有精确值)。
  • 新鲜全血组患者比非新鲜全血组损伤更严重。
  • 8项比较新鲜全血与非新鲜全血的研究显示,总体生存率等效(OR 1.00,95%CI 0.65-1.55,p=0.61)。
  • 质量最高的研究(按生理和损伤特征匹配组)报告新鲜全血组死亡的调整OR为0.27(95%CI 0.13-0.58,p<0.01)。
  • 证据质量除一项研究为中等外,其余均为低或极低。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析(PROSPERO注册号CRD42019153849),采用随机效应模型计算OR和95%CI,使用GRADE系统评估证据质量。
  • 证据等级:系统评价/治疗性研究,level 3。
  • 证据质量:除一项研究为中等质量外,其余研究为低或极低质量。
  • 局限:作者指出证据稀缺且质量相对较低,可能低估潜在不良事件。

对床旁实践的改变

  • 步行血库新鲜全血可用于传统血液成分或储存、检测过的全血不易获得时的创伤性失血性休克复苏。
  • 作者认为步行血库可能是孤立社区和危机(包括COVID-19大流行)期间有吸引力的应急韧性措施,但仍建议谨慎。
  • 作者建议步行血库应接受前瞻性评估,以优化救治并指导政策。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Whole blood is optimal for resuscitation of traumatic hemorrhage. Walking Blood Banks provide fresh whole blood (FWB) where conventional blood components or stored, tested whole blood are not readily available. There is an increasing interest in this as an emergency resilience measure for isolated communities and during crises including the coronavirus disease 2019 pandemic. We conducted a systematic review and meta-analysis of the available evidence to inform practice.

METHODS: Standard systematic review methodology was used to obtain studies that reported the delivery of FWB (PROSPERO registry CRD42019153849). Studies that only reported whole blood from conventional blood banking were excluded. For outcomes, odds ratios (ORs) and 95% confidence interval (CI) were calculated using random-effects modeling because of high risk of heterogeneity. Quality of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation system.

RESULTS: Twenty-seven studies published from 2006 to 2020 reported >10,000 U of FWB for >3,000 patients (precise values not available for all studies). Evidence for studies was "low" or "very low" except for one study, which was "moderate" in quality. Fresh whole blood patients were more severely injured than non-FWB patients. Overall, survival was equivalent between FWB and non-FWB groups for eight studies that compared these (OR, 1.00 [95% CI, 0.65-1.55]; p = 0.61). However, the highest quality study (matched groups for physiological and injury characteristics) reported an adjusted OR of 0.27 (95% CI, 0.13-0.58) for mortality for the FWB group (p < 0.01).

CONCLUSION: Thousands of units of FWB from Walking Blood Banks have been transfused in patients following life-threatening hemorrhage. Survival is equivalent for FWB resuscitation when compared with non-FWB, even when patients were more severely injured. Evidence is scarce and of relative low quality and may underestimate potential adverse events. Whereas Walking Blood Banks may be an attractive resilience measure, caution is still advised. Walking Blood Banks should be subject to prospective evaluation to optimize care and inform policy.

LEVEL OF EVIDENCE: Systematic/therapeutic, level 3.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Naumann DN, Boulton AJ, Sandhu A, et al. Fresh whole blood from walking blood banks for patients with traumatic hemorrhagic shock: A systematic review and meta-analysis. J Trauma Acute Care Surg. 2020. PMID: 32590558. doi:10.1097/TA.0000000000002840

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。